Choueiri, Toni K. http://orcid.org/0000-0002-9201-3217
Bauer, Todd M.
Papadopoulos, Kyriakos P.
Plimack, Elizabeth R. http://orcid.org/0000-0002-7618-0744
Merchan, Jaime R.
McDermott, David F. http://orcid.org/0000-0002-2675-5095
Michaelson, M. Dror http://orcid.org/0000-0001-9249-6338
Appleman, Leonard J.
Thamake, Sanjay
Perini, Rodolfo F.
Zojwalla, Naseem J.
Jonasch, Eric http://orcid.org/0000-0003-0943-2806
Funding for this research was provided by:
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA
Article History
Received: 9 September 2020
Accepted: 17 March 2021
First Online: 22 April 2021
Change Date: 27 August 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-021-01516-1
Competing interests
: T. K. C. has served on advisory boards, provided consultation and received clinical trial grants from AstraZeneca, Bristol Myers Squibb, Exelixis, Pfizer, Janssen, Merck Sharp & Dohme, Eli Lilly, Eisai, Novartis, GlaxoSmithKline, Infinity, Surface Oncology and EMD Serono; has stock ownership in Pionyr and Tempest; has a patent pending and issues related to biomarkers of immuno-oncology; and sits on the National Comprehensive Cancer Network (NCCN) kidney panel. T. K. C. received royalties from Up-To-Date. T. K. C. received fees for continuing medical education (CME)-accredited activities such as Medscape, OncLive, Research to Practice and others. T. M. B. has received research funding from Peloton Therapeutics, a wholly owned subsidiary of Merck & Co., Inc., Daiichi Sankyo, MedPacto, Incyte, Mirati Therapeutics, MedImmune, AbbVie, AstraZeneca, MabVax, Stemline Therapeutics, Merck Sharp & Dohme, Eli Lilly, GlaxoSmithKline, Novartis, Genentech, Deciphera, Merrimack, Immunogen, Phosplatin Therapeutics, Calithera Biosciences, Koltan Pharmaceuticals, Principia Biopharma, Immunocore, Roche, Aileron Therapeutics, Bristol Myers Squibb, Amgen, Onyx, Sanofi, Boehringer Ingelheim, Astellas Pharma, Five Prime Therapeutics, Jacobio, Top Alliance Biosciences, Janssen, Clovis Oncology, Takeda, Karyopharm Therapeutics, Foundation Medicine, ARMO BioSciences, Leap Therapeutics, Ignyta, Moderna Therapeutics, Pfizer, Loxo and Bayer; has been a consultant for Eli Lilly, Bristol Myers Squibb, Foundation Medicine, Leap Therapeutics, Ignyta, Moderna Therapeutics, Pfizer, Loxo, Bayer, Guardant Health, Exelixis and Blueprint Medicines; and served on speaker bureaus for Bayer and Eli Lilly. K. P. P. has received research funding from Merck Sharp & Dohme, ARMO BioSciences, ArQule, Amgen, Calithera Biosciences, Incyte, Jounce, ADC Therapeutics, 3D Medicines, Syros Pharmaceuticals, Mersana, MabSpace Biosciences, Bayer, Daiichi Sankyo, AnHeart, Basilea, F-star, Linnaeus, Mirati and Tempest Therapeutics; and has served on advisory boards for ArQule, Bayer and Basilea. E. R. P. has received research funding from Peloton Therapeutics, a wholly owned subsidiary of Merck & Co., Inc., Acceleron, AstraZeneca, Bristol Myers Squib, Merck Sharp & Dohme, Pfizer, Astellas and Genentech; has been a consultant for Bristol Myers Squibb, Exelixis, Flatiron, Genentech, Incyte, Janssen, Merck Sharp & Dohme and Seattle Genetics; has served on data safety monitoring committees for AstraZeneca, Infinity Pharma and Pfizer; has a patent pending for methods for screening patients with muscle invasive bladder cancer for responsiveness to neoadjuvant chemotherapy; and has received fees for CME-accredited activities for AUA, Clinical Care Options, Fox Chase Cancer Center, Georgetown, GU ASCO, Medscape, Mt. Sinai School of Medicine, NCCN, Ohio State University, Omniprex, OncLive, PER, PriME Oncology, Research to Practice, Spire Learning and the University of Pennsylvania. J. R. M. has received research funding from Peloton Therapeutics, a wholly owned subsidiary of Merck & Co., Inc., Corvus Pharmaceuticals, Silagen, Tizona, Eisai, Genentech, Pfizer, Vyriad, Replimune, Calithera Biosciences, Rexahn Pharmaceuticals, Seattle Genetics, Astellas, Tocagen, Novartis and Eli Lilly; and has served on an advisory board for Exelixis. D. F. M. has received research funding from Bristol Myers Squibb, Merck Sharp & Dohme, Genentech, Pfizer, Exelixis, X4 Pharma and Alkermes; and has been a consultant for Bristol Myers Squibb, Pfizer, Merck Sharp & Dohme, Alkermes, EMD Serono, Eli Lilly and Iovance Biotherapeutics. M. D. M. has received research funding from Merck Sharp & Dohme and has served on advisory boards for Merck Sharp & Dohme, Pfizer, Novartis, Exelixis and Eisai. L. J. A. has nothing to disclose. S. T. is an employee of Peloton Therapeutics, a wholly owned subsidiary of Merck & Co., Inc. R. F. P. is an employee of and has stock ownership in Merck Sharp & Dohme, a subsidiary of Merck & Co., Inc. N. J. Z. was an employee of Merck & Co., Inc. at the time of this analysis. E.J. has received research funding from Arrowhead Pharmaceuticals, research funding and consultation fees from Aravive, Merck, and Novartis, consultation fees from Aveo, Eisai, Ipsen, NiKang and Pfizer, and has received royalties from UpToDate and consultation fees from Elsevier (PracticeUpdate).